Drug Profile
Research programme: acetylation inhibitors - Acylin Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Acylin Therapeutics
- Class Small molecules
- Mechanism of Action Acetyltransferase inhibitors; Acyltransferase inhibitors; Ghrelin O-acyltransferase inhibitors; P300-CBP transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Metabolic disorders; Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Metabolic-disorders in USA
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in USA